(75.101.220.230)
Users online: 2258    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2015, Volume : 8, Issue : 1
First page : ( 44) Last page : ( 50)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2015.00009.8

A Comparative Evaluation of Safety, Efficacy and Cost Effectiveness of Three add on Treatment Regimens in Type 2 Diabetics; not Controlled by Metformin Alone

Dr. Suraj B1,*, Dr. Tripathi C D2, Dr. Biswas Krishna3, Dr. Padhy B M4, Dr. Arora Tarun5

1Department of Pharmacology, ESIC Medical College, Gulbarga, 585106, India

2Department of Pharmacology, VMMC & Safdarjung Hospital, New Delhi, 110029, India

3Department of Endocrinology, VMMC & Safdarjung Hospital, New Delhi, 110029, India

4Department of Pharmacology, AIIMS, Bhubaneswar, Orissa, 751019, India

5Department of Pharmacology, LHMC, New Delhi, 110001, India

*Corresponding Author E-mail: drsurajpanchal@gmail.com

Abstract

Background and Objectives

Type 2 diabetes mellitus (T2DM) is progressive multisystem disease requiring multiple antihyperglycaemic agents to attain or maintain glycaemic control. With the increase in incidence of T2DM and availability of a number of drugs as second line therapy there is considerable increase in the use of newer, more costly oral hypoglycaemic agents, which has resulted in substantial increase in associated costs to patients. The present study was aimed to evaluate the safety, efficacy and cost effectiveness of oral antidiabetic regimens.

Methods

This study was an observational, prospective and longitudinal in nature carried out to study the safety, efficacy and cost effectiveness of three add on treatment regimens [i.e with sulfonylurea (group 1), glitazones (group 2) and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) (group 3)] in patient with T2DM not controlled by metformin alone which included 150 subjects (approximately 50 patient in each group). The comparisons were conducted between these three groups for glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), post prandial glucose (PPG), costs and lipid profile.

Results

At week 12, the significant reduction in HbA1c was found in group 1 (−1.19%) when compared to group 2 (0.71%) and group 3 (−0.70%). Also significantly greater reductions were observed in group 1 in FPG level (−38.88%) when compared to group 3 and in PPG level (−54.08%) when compared to group 2 and group 3. Comparison of three groups showed significant increase in the cost in group 3 as compared to group 1 and group 2, with the highest cost effectiveness measured in group 1 (p<0.0001).

Interpretation and Conclusions

Group 1 resulted in significantly greater reductions in HbA1c, FPG and PPG levels and highest cost effectiveness when compared with group 2 and group 3 in patients with T2DM.

Top

Keywords

Add on, Cost effectiveness, Metformin, Type 2 diabetes.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
447,035,461 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.